Ovoca Bio (CDI) (OVB) RNS Announcements

Add to Alert list
Date Time Source Announcement
28 Dec 2001 05:42 PM
RNS
Interim Results
02 Nov 2001 04:05 PM
RNS
Redenomination to Euro
25 Oct 2001 12:00 PM
RNS
Re; Negotiations
10 Sep 2001 03:34 PM
RNS
Preliminary Results 28/2/01
27 Jun 2001 04:04 PM
RNS
Appointment
08 Jun 2001 12:53 PM
RNS
Placing of New Shares
17 Jan 2001 07:30 AM
RNS
Proposed Joint Venture
02 Jan 2001 08:26 AM
RNS
Interim Results
26 Oct 2000 02:45 PM
RNS
AGM Statement
25 May 2000 02:29 PM
RNS
Brochure of Particulars
06 Jan 2000 11:40 AM
RNS
Directors' Dealings
29 Dec 1999 03:39 PM
RNS
Interim Results - 6 Months to 31 August 1999
21 Dec 1999 08:05 AM
RNS
Drilling Programme Centred on West-Limerick
28 Oct 1999 05:29 PM
RNS
Resolutions Passed at AGM
04 Oct 1999 06:31 PM
RNS
Directors' Dealings
30 Sep 1999 05:57 PM
RNS
Directors' Dealings
28 Sep 1999 04:13 PM
RNS
Directors' Dealings
03 Sep 1999 10:59 AM
RNS
Circ re Notice of AGM
02 Sep 1999 08:36 AM
RNS
Doc re Report and Accounts

Ovoca Bio PLC is a biopharmaceutical company focused on women's health, specifically developing novel treatments for female sexual dysfunction. Their lead product, Orenetide (BP-101), is a synthetic peptide administered via nasal spray, designed to treat hypoactive sexual desire disorder in premenopausal women. The company is incorporated in Ireland and operates in Ireland, the UK, and Russia. It is listed in London under the ticker OVB.

OVB share price was suspended from AIM on 7 May 2025.

 

UK 100

Latest directors dealings